(Q38068953)

28 August 2017

1 reference

title

Preclinical evaluation of MenB vaccines: prerequisites for clinical development (English)

1 reference

28 August 2017

Holly Sanders

1

1 reference

PubMed ID

23256737

28 August 2017

Patricia Kaaijk

series ordinal

2

1 reference

PubMed ID

23256737

28 August 2017

Germie Pjm van den Dobbelsteen

series ordinal

3

1 reference

28 August 2017

1 January 2013

1 reference

Expert Review of Vaccines

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

1

1 reference

28 August 2017

31-42

1 reference

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

28 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Identification of novel antigens that protect against systemic meningococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Study designs for the nonclinical safety testing of new vaccine products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Non-clinical vaccine safety assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

International validation of novel pyrogen tests based on human monocytoid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

A rapid 'one-plate' in vitro test for pyrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with limulus amebocyte lysate gelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Meningococcal surrogates of protection--serum bactericidal antibody activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Human immunity to the meningococcus. II. Development of natural immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Effect of Neisseria meningitidis fur mutations on global control of gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Iron transport systems in Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Experimental disease models for the assessment of meningococcal vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Experimental meningococcal sepsis in congenic transgenic mice expressing human transferrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Transgenic mice expressing human transferrin as a model for meningococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Imaging of disease dynamics during meningococcal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

CD46 in meningococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.137

21 January 2018

Identifiers

DOI

10.1586/ERV.12.137

1 reference

28 August 2017

1 reference

PubMed ID

23256737